Know Labs, Inc. - KNW STOCK NEWS

Know Labs, Inc. announces the results of its technical feasibility study on its Bio-RFID™ sensor for non-invasive blood glucose monitoring. The study demonstrates stable and repeatable results in predicting blood glucose concentrations using the Dexcom G6® as a reference device. The mean absolute relative difference (MARD) was 20.6% and 46% of predictions were within the FDA's recommended limit for accuracy.

Know Labs, Inc. (KNW) has announced successful results from a proof-of-principle study demonstrating the accuracy of its proprietary Bio-RFID technology in non-invasive medical diagnostics. Conducted in collaboration with Mayo Clinic, the study, titled "Detecting Unique Analyte-Specific Radio Frequency Spectral Responses in Liquid Solutions," showcased a remarkable 100% accuracy rate in measuring various analytes in vitro. This breakthrough technology captures molecular signatures using radio waves, with glucose monitoring being its first application. Market trends highlighting the need for affordable, accurate non-invasive healthcare solutions further bolster the significance of these results. The full study awaits peer-review publication.

Know Labs, Inc. (NYSE American: KNW) has formed a new Scientific Advisory Board (SAB) featuring leading experts in medical technology and human health. This board aims to enhance Know Labs' efforts in algorithm refinement, device development, and clinical trial design for its Bio-RFID technology, which aims to offer non-invasive glucose monitoring. The SAB includes esteemed members like Dr. Benjamin Smarr and Dr. Mark Aloia, who bring extensive backgrounds in research and technology. Know Labs emphasizes 2023 as a year of prioritizing external validation of its non-invasive diagnostic technology.

Know Labs, Inc. (NYSE American: KNW) reported its financial results for Q1 2023, revealing a net loss of $3.82 million, a decrease from a $5.36 million loss in Q1 2022. This translates to a loss per share of $0.08, compared to $0.15 the previous year. Research and development expenses surged to $1.74 million from $886,000, attributed to staffing and Bio-RFID technology development aimed at FDA trials. Cash and equivalents decreased to $9.68 million from $12.59 million. The company estimates it has sufficient cash to fund operations until February 14, 2024. Shareholder equity fell to $7.1 million from $9.9 million in the prior quarter.

Know Labs, Inc. (AMEX: KNW) is set to hold a webcast on February 14, 2023, at 1:30 PM PT, to discuss business updates and results from Q1 FY 2023, which ended on December 31, 2022. The webcast will be accessible live and for replay at knowlabs.co/investors. The company specializes in non-invasive medical diagnostic technology, utilizing its Bio-RFID™ technology to develop wearable and mobile diagnostics. Its first product is a non-invasive glucose monitor awaiting FDA clearance. Investors are encouraged to submit questions during the webcast for further insights.

Know Labs, Inc. (NYSE American: KNW) has provided an update on its strategic partnerships to advance the FDA clearance for its innovative non-invasive glucose monitoring devices. The company collaborates with experts in data science, regulatory affairs, and product design, aiming to transform patient care. Key partners include Igor Institute, Bould Design, Edge Impulse, and NOVUS Management Group, who contribute expertise in areas like engineering and algorithm development. Know Labs plans to validate its Bio-RFID technology for accurate glucose measurement in 2023 while continuing to build its advisory board. The non-invasive glucose monitor could revolutionize diabetes management.

Know Labs, Inc. (NYSE American: KNW) announced executive leadership changes aimed at accelerating the development of its Bio-RFID™ technology. Effective immediately, Ron Erickson, the founder, has been appointed CEO, bringing nearly 20 years of experience. Masanori King Takee is now Chief Technology Officer, focusing on software and data science to refine Bio-RFID algorithms. Jessica English joins as Chief Marketing Officer to lead marketing efforts, while Leo Trautwein is promoted to Chief Commercial Officer. The company aims to validate its technology through data science and partnerships for clinical trials in 2023.

Know Labs, Inc. (NYSE American: KNW) has appointed founder Ron Erickson as the new CEO, succeeding Phil Bosua, who transitions to a technology advisor role. Erickson, with nearly 20 years at Know Labs and over 30 years in leadership roles, emphasized the importance of accelerating product development for the Bio-RFID technology, aimed at non-invasive glucose monitoring. The company is focused on FDA clearance and enhancing its product development team in 2023. The Board supports this leadership change, highlighting an aggressive strategy to transform medical diagnostics and enhance shareholder value.